Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CITIUS ONCOLOGY, INC. (CTOR)

Citius Oncology: LYMPHIR wholesaler units rise 120% to 792 in fiscal Q4 2026

Positive Impact 3 of 5 earnings Written later

Citius Oncology reported preliminary, unaudited LYMPHIR unit sales to U.S. wholesalers of 792 units for the fiscal fourth quarter ended September 30, 2026, up 120% from 360 units in the prior quarter. The figures are not audited, and the company will report full fiscal fourth quarter and fiscal 2026 results in December 2026 in its Form 10-K, so the final numbers may differ.

Key points

  • Wholesaler units purchased were 792 for the three months ended September 30, 2026, versus 360 for the three months ended June 30, 2026.
  • LYMPHIR vials ordered by prescribing centers from wholesalers were 950, compared with 926 for the fiscal third quarter.
  • 54 institutions had ordered LYMPHIR as of the release date, up from 44 as of August 14, 2026. The company's revenue is recognized on wholesaler sales, net of estimated gross-to-net adjustments.

The filing

CompanyCITIUS ONCOLOGY, INC. (CTOR)
Form8-K, current report
Filed with the SECOct 26, 2026, 4:05 PM ET
Accession number0001213900-26-112477

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.